TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.7024
-0.0076 (-1.07%)
As of 2:19PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7100
Open0.7300
Bid0.7000 x 1400
Ask0.6999 x 1000
Day's Range0.6950 - 0.7999
52 Week Range0.5300 - 5.1100
Volume1,857,017
Avg. Volume943,070
Market Cap7.041M
Beta (3Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-3.0790
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • ACCESSWIRE15 days ago

    Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies

    NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.

  • GlobeNewswire23 days ago

    Tonix Pharmaceuticals to Present at the MicroCap Conference

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the MicroCap Conference being held October 1-2, 2018, in New York City. A live webcast and subsequent archived recording of the presentation will be available under the Presentations & Events tab of the Investors section of the Tonix Pharmaceuticals website at www.tonixpharma.com.

  • GlobeNewswire29 days ago

    Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

    NEW YORK, Sept. 20, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti ...

  • GlobeNewswirelast month

    Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors, effective immediately.  Dr. Olukotun assumes the seat held by Dr. Ernest Mario, who has stepped down from the position of company director that Dr. Mario has held since 2011. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Olukotun to the Tonix Board, as he brings 30 years of biopharmaceutical operational and leadership experience that will be invaluable to Tonix as we grow the company.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

    NEW YORK, Aug. 30, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences ...

  • Zacks Small Cap Research2 months ago

    TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented…

    On August 21, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced a poster presentation at the 2018 Military Health System Research Symposium that included results from the Phase 3 HONOR trial and retrospective analyses from the HONOR trial and the Phase 2 AtEase trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) in patients with posttraumatic stress disorder (PTSD). In July 2018, the company announced that the HONOR trial was stopped early due to a lack of separation between the placebo group and treated group at the 12-week timepoint.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Announces Director Stepping Down

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Samuel Saks, M.D. has stepped down from the Company’s board of directors, effective August 21, 2018. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “On behalf of the Board and management, I would like to thank Sam for his many contributions and dedicated service to Tonix. “It has been my privilege to have worked with the board and management team of Tonix Pharmaceuticals,” said Dr. Saks.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SPDR S&P Retail (NYSE: XRT ) could see increased volatility ...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) is presenting a poster today at the 2018 Military Health System Research Symposium (MHSRS) in Kissimmee, Fla.  The poster, entitled “Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies” includes results and retrospective analyses from the Phase 3 P301 study (“HONOR”) and the Phase 2 P201 study (“AtEase”).  TNX-102 SL, or Tonmya*, is being developed for the treatment of posttraumatic stress disorder (PTSD).  The poster can be found on the Scientific Presentations page of Tonix’s website. Tonix recently reported that the Phase 3 P301 study was stopped at the pre-planned interim analysis because it did not achieve a study continuation threshold on the primary outcome of improvement in the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) at Week 12 in the modified intent-to-treat (mITT) population.  Today’s poster presentation reports that a retrospective analysis revealed a treatment effect in participants who experienced trauma less than or equal to nine years prior to screening (approximately 50% of the mITT population).  For this subgroup, the p-value of the primary endpoint at Week 12, using mixed model repeated measures with multiple imputation (MMRM with MI), was 0.039.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium

    NEW YORK, Aug. 15, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and Phase 2 AtEase Study in a poster, ...

  • Associated Press2 months ago

    Tonix: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 73 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

    HONOR Study Results to be Included in Poster Presentation at a Scientific Conference in August 2018. FDA Meeting in October 2018 Confirmed to Discuss New Phase 3 Study for Tonmya ® in PTSD. New Phase 3 ...

  • Zacks Small Cap Research2 months ago

    TNXP: HONOR Trial Stopped Early Following Interim Analysis...

    On July 27, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the Phase 3 HONOR trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) in patients with posttraumatic stress disorder (PTSD) has been stopped early due to a lack of separation between the placebo group and treated group at the 12-week timepoint. The company is planning to meet with the FDA (which we believe will take place during 4Q18) and will propose using the 4-week timepoint as the primary outcome measure for the next pivotal trial.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Amazon.com, Inc. (NASDAQ: AMZN ) was trading higher ...

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix), today announced that it will stop the Phase 3 HONOR study of Tonmya*(cyclobenzaprine HCl sublingual tablets) in military-related posttraumatic stress disorder (PTSD) due to inadequate separation from placebo on the primary endpoint at week 12. Preliminary safety data from these participants did not reveal any serious and/or unexpected adverse events and the decision to discontinue the study is not related to safety.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 17, 2018 / U.S. markets closed mostly lower on Monday, as upbeat economic data and the latest batch of corporate earnings failed to encourage investors. The Dow Jones Industrial ...

  • Why Tonix Pharmaceuticals Stock Soared Today
    Market Realist3 months ago

    Why Tonix Pharmaceuticals Stock Soared Today

    Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

  • Benzinga3 months ago

    Tonix Shares Surge On Fast Struck Status For Alzheimer's-Related Agitation Candidate

    Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) shares are surging higher on roughly 25 times their average volume after the biotech's pipeline candidate was granted  fast track designation by the Food ...

  • Bullish Insiders Bought More Of These Stocks In June
    Simply Wall St.4 months ago

    Bullish Insiders Bought More Of These Stocks In June

    Generally, insiders buying more shares in their own firm sends a bullish signal. A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the marketRead More...

  • Associated Press5 months ago

    Tonix: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 88 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...